Canadian Dollar eases from one-month top vs. firmer USD; surging Oil prices limit losses
The USD/CAD pair rebounds from the vicinity of mid-1.3500s, or a nearly one-month low touched during the Asian session on Monday, though it lacks follow-through buying. Spot prices struggle to build on the bounce beyond the 1.3600 mark amid mixed fundamental cues, which warrants some caution for bullish traders.
The escalating Middle East conflict offsets Friday's dismal US Nonfarm Payrolls (NFP) report and lifts the safe-haven US Dollar (USD) to a fresh high since November 2025. Furthermore, a surge in Crude Oil prices fuel inflation concerns and forces investors to push back their expectations about the likely timing of the next rate cut by the US Federal Reserve (Fed), and continues to push the US Treasury bond yields. This provides an additional boost to the Greenback, which, in turn, is seen as a key factor acting as a tailwind for the USD/CAD pair.
Meanwhile, Crude Oil prices surged over 25% intraday, beyond the $110 mark, to a nine-month peak on Monday amid concerns about supply disruptions from the Strait of Hormuz. This is seen underpinning the commodity-linked Loonie and acting as a headwind for the USD/CAD pair. Moreover, Friday's break below a multi-week-old trading range support makes it prudent to wait for strong follow-through buying before confirming that spot prices have formed a near-term bottom and before positioning for any meaningful recovery.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
AMD (AMD.US) Surpasses $1 Trillion Market Cap and Begins Competing for "Computing Power Definition Rights"! Officially Announces $8.2 Billion Acquisition of Fei-Fei Li's World Labs
AMD has agreed to acquire World Labs for $8.2 billion, thereby gaining access to the artificial intelligence startup founded by industry pioneer and researcher Fei-Fei Li. This acquisition is expected to help AMD plan its future hardware launches by bringing in a team of top researchers and their models, as well as deep insights into trends in the field of artificial intelligence.
A Major Reversal Amid the U.S. Bond Selloff! Bond Market Veteran Bianco Turns Bullish for the First Time in Six Years, Calling 5% Yield a "Value Buy Opportunity"
Currently, as benchmark U.S. Treasury yields surge to their highest levels in nearly two decades, bond market veteran Jim Bianco has loosened his bearish stance for the first time and is gradually building long positions as a "value buyer."
Crypto prices
More
